Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM

Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.

Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news